Dr. Marty Makary, the Food and Drug Administration commissioner appointed by former President Donald Trump, has announced his resignation following a tenure marked by conflicts with pharmaceutical CEOs, vaping lobbyists, and anti-abortion groups. The decision, reported by WorldNews Service, comes amid growing pressure from various stakeholders who opposed his regulatory approach.
Makary's Contentious Tenure
Makary, a surgeon and author, was confirmed as FDA commissioner in 2025. His leadership drew criticism from pharmaceutical executives who felt his policies on drug approvals and pricing were too aggressive. Vaping lobbyists also opposed his push for stricter regulations on e-cigarettes, while anti-abortion groups expressed dissatisfaction with his stance on reproductive health issues.
Reactions from Industry and Advocacy Groups
Pharmaceutical CEOs had been vocal in their opposition to Makary's efforts to accelerate generic drug approvals and lower prescription costs. The vaping industry, meanwhile, criticized his proposed ban on flavored e-cigarettes, arguing it would harm small businesses. Anti-abortion groups accused him of not doing enough to restrict access to abortion medications.
In a statement, Makary said he was proud of his work at the FDA but acknowledged the challenges of leading the agency during a politically charged time. He did not specify his future plans but hinted at returning to academia and writing.
Impact on FDA Policies
Under Makary, the FDA approved several controversial drugs and implemented new guidelines for medical devices. His resignation raises questions about the continuity of these policies, especially as the Biden administration considers new leadership for the agency.
The White House has not yet announced a replacement. Analysts expect the next commissioner to face similar challenges in balancing public health with industry interests.
